Harmony Biosciences (HRMY) vs Nurix Therapeutics (NRIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 131.2% versus a gain of 45.4%. Over five years, HRMY leads with a -0.2% price change compared with -21.2% for NRIX. Harmony Biosciences is the larger company by market cap ($2.27 billion vs $2.24 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | NRIX |
|---|---|---|
| Share price | $38.90 | $21.61 |
| Market cap | $2.27B | $2.24B |
| 1-day change | -1.12% | -4.93% |
| YTD return | +5.13% | +19.82% |
| 1-year return | +45.43% | +131.23% |
| 5-year return | -0.15% | -21.16% |
| P/E ratio (TTM) | 12.55 | — |
| Forward P/E | 5.55 | — |
| EPS (TTM) | $3.10 | $-3.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.49 | $28.23 |
| 52-week low | $25.52 | $9.00 |
| Distance from 52-week high | -10.55% | -23.45% |
| Analyst consensus | buy | none |
| Avg. price target upside | +22.47% | +57.01% |
| Average volume | 888.54K | 1.27M |
| Shares outstanding | 58.24M | 103.78M |
| Employees | 293 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRIX has outperformed HRMY by 85.8 percentage points over the past year.
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
HRMY vs NRIX FAQ
Which is bigger, Harmony Biosciences or Nurix Therapeutics?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $2.27B compared with $2.24B for Nurix Therapeutics (NRIX).
Which stock has performed better over the past year, HRMY or NRIX?
NRIX returned +131.23% over the past 12 months, compared with +45.43% for HRMY (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and Nurix Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.